Status:
COMPLETED
Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery
Lead Sponsor:
University of Minnesota
Conditions:
New Onset Atrial Fibrillation
Anesthesia, Local
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose if this pilot study is to determine if a perioperative infusion of 0.2% ropivacaine via bilateral T3 paravertebral catheters can decrease the incidence of new onset atrial fibrillation fol...
Detailed Description
Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200...
Eligibility Criteria
Inclusion
- \- Participants must be undergoing one of the following elective or urgent (but not emergent) surgeries: A) Primary Coronary Artery Bypass Graft (CABG) B) Primary Surgical Aortic Valve Replacement (sAVR) C) Primary Surgical Mitral Valve Replacement (sMVR) D) Combined CABG \& surgical valve replacement
Exclusion
- History of atrial fibrillation or flutter
- Infective endocarditis
- Left ventricular ejection fraction (LVEF) \< 30%
- Emergency surgery
- Redo surgery
- Contraindication to block placement including local anesthetic allergy, bleeding diathesis (physiologic or iatrogenic)
- Body mass index \> 35kg/m2
- Pregnancy
Key Trial Info
Start Date :
April 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 8 2025
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04472299
Start Date
April 9 2021
End Date
July 8 2025
Last Update
August 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455